Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Hematologic Reference Intervals Defined for Newborns

By LabMedica International staff writers
Posted on 05 Jan 2021
Laboratory tests leverage 60% to 70% of medical decisions and one of the most often ordered and impactful tests is the complete blood count (CBC). More...
These decisions require that clinicians have a standard for interpreting laboratory test results for their patients.

Ethical constraints exist for performing an unnecessary needle stick and collecting non-clinically indicated blood samples from this vulnerable newborn population. Many newborn CBC Reference Intervals (RI) publications have been retrospective and some authors cite this as one of their cardinal limitations.

A team of medical scientists associated with the Banner – University Medical Center Phoenix, (Phoenix, AZ, USA) conducted a prospective study at an academic tertiary care center, and hematology samples were collected from 120 participants deemed to be normal healthy term newborns. Study enrollment occurred between May 24, 2016, and November 1, 2017. A total of 170 blood specimens were sent to the laboratory.

The team used a single Sysmex XN-1000 Automated Hematology Analyzer (Sysmex America, Lincolnshire, IL, USA) to generate a CBC with white blood cell (WBC) differential for each newborn, including the advanced hematology parameters. Distributions were assessed for normality and tested for outliers. Reference intervals were values between the 2.5th percentile and 97.5th percentile.

The scientists reported that the novel reference intervals obtained for this study population are as follows: absolute immature granulocyte count, 80/μL to 1,700/μL; immature granulocyte percentage, 0.6% to 6.1%; reticulocyte hemoglobin equivalent, 31.7 to 38.4 pg; immature reticulocyte fraction, 35.9% to 52.8%; immature platelet count, 4.73 × 103/μL to 19.72 × 103/μL; and immature platelet fraction, 1.7% to 9.8%.

The authors concluded their prospective study has defined hematologic reference intervals for this newborn population, including new advanced clinical parameters from the Sysmex XN-1000 Automated Hematology Analyzer. These reference intervals are proposed as the new standard and can serve as a strong foundation for continued studies to further explore their value in diagnosing and managing morbidities such as sepsis, anemia, and thrombocytopenia. The study was published in the January, 2021 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
Banner – University Medical Center Phoenix
Sysmex America



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Gold Member
Radial Immunodiffusion Assay
Radial Immunodifusion - C3 ID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.